Table 1.

Models of neuroinflammation in which NK-1R antagonists and/or genetic deficiency have shown reduced disease severity.

CNS disorder	Model	Organism	Antagonist	Knockout	Effect	Reference
Neurocysticersosis	T. crassiceps	Mouse		NK-1R Substance P	Lower granuloma volume. Less IL-1β, IL-6, TNF-α.	Garza et al. (2010)
African trypanosomiasis	T. brucei + diminazene	Mouse	RP-67580		Reduced astrogliosis, clinical score, cellularity.	Kennedy et al. (1997)
Bacterial meningitis	S. pneumoniae N. meningiditis B. burgdorferi	Mouse	L703,606	NK-1R	Reduced BBB permeability, astrogliosis, microgliosis, cellularity, demyelination, IL-6, TNF-α. More IL-10.	Chauhan et al. (2008) Chauhan et al. (2011)
Multiple sclerosis	EAE	Mouse	SR 14033	NK-1R	Greater mobility. Decreased MOG specific T-cells.	Reinke et al. (2006)
			CP-96,345		Less clinical and histological signs.	Nessler et al. (2006)